DANIEL LEUNG to Cohort Studies
This is a "connection" page, showing publications DANIEL LEUNG has written about Cohort Studies.
Connection Strength
0.255
-
Risk factors for more rapid progression of severe liver fibrosis in children with cystic fibrosis-related liver disease: A multi-center study validated by liver biopsy. Liver Int. 2023 06; 43(6):1277-1286.
Score: 0.111
-
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort. Hepatol Commun. 2024 Nov 01; 8(11).
Score: 0.031
-
Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease. J Cyst Fibros. 2023 07; 22(4):745-755.
Score: 0.028
-
Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study. J Pediatr Gastroenterol Nutr. 2021 09 01; 73(3):395-402.
Score: 0.025
-
Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease. J Pediatr Gastroenterol Nutr. 2019 09; 69(3):351-357.
Score: 0.022
-
Pulmonary findings in infants with cystic fibrosis during the first year of life: Results from the Baby Observational and Nutrition Study (BONUS) cohort study. Pediatr Pulmonol. 2019 05; 54(5):581-586.
Score: 0.021
-
Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr. 2018 04; 66(4):657-663.
Score: 0.020